Skip to search formSkip to main contentSkip to account menu

KRN 321

Known as: KRN-321, KRN321 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

darbepoetin alfa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
健康成人における KRN321（ダルベポエチンアルファ）360 μg／mL と 120 μg／mL の生物学的同等性試験
Background KRN321 is a hyperglycosylated analog of recombinant human erythropoietin that stimulates red cell production. Its… 
2011
2011
Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan
BackgroundDarbepoetin alfa (KRN321) is a recombinant protein that stimulates erythropoiesis by the same mechanism as endogenous… 
2008
2008
Darbepoetin Alfa (KRN321) Administered Intravenously Once Monthly Maintains Hemoglobin Levels in Peritoneal Dialysis Patients
Abstract:  Darbepoetin alfa (KRN321) is a novel molecule that stimulates erythropoiesis by the same mechanism as endogenous… 
2008
2008
新たな腎性貧血治療薬 (ダルベポエチンアルファ : KRN321) の臨床試験成績の概要
2007
2007
Darbepoetin Alfa Effectively Maintains Hemoglobin Concentrations at Extended Dose Intervals Relative to Intravenous rHuEPO in Japanese Dialysis Patients
Abstract:  Darbepoetin alfa (KRN321) is a novel molecule that stimulates erythropoiesis by the same mechanism as endogenous… 
2007
2007
Pharmacokinetic study of darbepoetin alfa: Absorption, distribution, and excretion after a single intravenous and subcutaneous administration to rats
KRN321 is a hyperglycosylated analogue of recombinant human erythropoietin (rHuEPO, epoetin alfa), and its absorption… 
2007
2007
Pharmacokinetic and Pharmacodynamic Properties of Intravenous Darbepoetin Alfa (KRN321) in Japanese Hemodialysis Patients
This article describes the pharmacokinetics, pharmacodynamics of darbepoetin alfa, a novel erythropoietin analogue showing a long… 
2007
2007
KRN321 (Darbepoetin alfa) 第II/III相臨床試験-血液透析患者における rHuEPO 製剤との無作為化二重盲検比較試験-
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)